The motivation behind the review (PRWeek, 6 January) remains unknown.
The pitch was overseen by GSK staff including Anna Gibbins, who joined as global PR director in the firm's global commercial strategy
division late last year.
The US Food and Drug Administration last year urged doctors to restrict prescription of Advair and asked that stronger warnings be added to packaging. GSK disagrees with the FDA's view that the asthma medicine increases the chance of deadly complications.